- Home
- KGEI vs ANNX Comparison
KGEI vs ANNX Comparison
Compare KGEI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- ANNX
- Stock Information
- Founded
- KGEI 2008
- ANNX 2011
- Country
- KGEI United States
- ANNX United States
- Employees
- KGEI N/A
- ANNX N/A
- Industry
- KGEI
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- ANNX Health Care
- Exchange
- KGEI Nasdaq
- ANNX Nasdaq
- Market Cap
- KGEI 254.9M
- ANNX 253.8M
- IPO Year
- KGEI N/A
- ANNX 2020
- Fundamental
- Price
- KGEI $5.56
- ANNX $3.09
- Analyst Decision
- KGEI Strong Buy
- ANNX Strong Buy
- Analyst Count
- KGEI 1
- ANNX 4
- Target Price
- KGEI $11.00
- ANNX $13.00
- AVG Volume (30 Days)
- KGEI 123.4K
- ANNX 2.4M
- Earning Date
- KGEI 11-11-2025
- ANNX 11-13-2025
- Dividend Yield
- KGEI N/A
- ANNX N/A
- EPS Growth
- KGEI 35.27
- ANNX N/A
- EPS
- KGEI 0.54
- ANNX N/A
- Revenue
- KGEI $57,936,000.00
- ANNX N/A
- Revenue This Year
- KGEI $14.07
- ANNX N/A
- Revenue Next Year
- KGEI $26.69
- ANNX N/A
- P/E Ratio
- KGEI $10.28
- ANNX N/A
- Revenue Growth
- KGEI 6.52
- ANNX N/A
- 52 Week Low
- KGEI $2.91
- ANNX $1.29
- 52 Week High
- KGEI $9.89
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- KGEI 47.89
- ANNX 60.42
- Support Level
- KGEI $5.15
- ANNX $2.91
- Resistance Level
- KGEI $5.73
- ANNX $3.38
- Average True Range (ATR)
- KGEI 0.23
- ANNX 0.24
- MACD
- KGEI -0.00
- ANNX 0.02
- Stochastic Oscillator
- KGEI 54.91
- ANNX 61.87
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.